The company reported a net loss of $33.2 million, which is less than the same period last year. During the past year, BioMimetic Therapeutics received FDA clearance on several orthopedic devices and has been working with the regulatory body to obtain approval for its Augment Bone Graft, which was cleared by the Australian Therapeutics Goods Administration during the fourth quarter of last year.
More recently, the company has announced clearance internationally and has made progress on studies for their products.
More Articles on Orthopedic Devices:
17 Spine Devices Receive FDA 510(k) Clearance in February
TranS1 Reports 32% Drop in 4Q Revenue
American Joint Replacement Registry Now Includes 19k Procedures
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.